新型B细胞淋巴瘤-2抑制剂——lisaftoclax
A novel inhibitor of B-cell lymphoma-2:lisaftoclax
丁绍越 1焉玉超 1张连哲 1程卯生 1刘洋1
作者信息
- 1. 沈阳药科大学 制药工程学院 基于靶点的药物设计与研究教育部重点实验室,沈阳 110016
- 折叠
摘要
慢性淋巴细胞白血病(CLL)和小淋巴细胞淋巴瘤(SLL)是常见的血液肿瘤疾病.B细胞淋巴瘤-2(Bcl-2)是一种在血液肿瘤中高表达的关键细胞凋亡调节蛋白,lisaftoclax是一种Bcl-2抑制剂.在前期的临床试验中,lisaftoclax表现出良好的疗效和安全性,即使在1200 mg剂量下也未发生剂量限制性毒性.目前该药物正处于Ⅲ期临床试验的招募阶段.本文对该药物的基本信息、作用机制、药动学、有效性和安全性等方面进行概述.
Abstract
Chronic lymphocytic leukaemia(CLL)and small lymphocytic lymphoma(SLL)are common haematological tumour diseases.Lisaftoclax is an inhibitor of B-cell lymphoma-2(Bcl-2),a key apoptosis-regulating protein that is highly expressed in haematological malignancies.In early clinical trials,lisaftoclax demonstrated promising efficacy and safety,with no dose-limiting toxicity observed even at 1200 mg.The drug is currently in the recruitment phase of a phase Ⅲ clinical trial.This article provides an overview of the basic information,mechanism of action,pharmacokinetics,efficacy,and safety of the drug.
关键词
lisaftoclax/B细胞淋巴瘤-2抑制剂/慢性淋巴细胞白血病/小淋巴细胞淋巴瘤Key words
lisaftoclax/inhibitor of B-cell lymphoma-2/chronic lymphocytic leukaemia/small lymphocytic lymphoma引用本文复制引用
出版年
2024
NETL
NSTL
万方数据